No advantage of continuous vs intermittent meropenem in critically ill patients – the MERCY trial
1. The MERCY trial revealed that continuous infusion of meropenem does not confer a significant advantage over intermittent administration in reducing mortality and preventing new antibiotic-resistant bacteria in patients with either septic shock or sepsis. 2. This randomized control trial provides contrary evidence to previous systematic reviews and meta-analyses that found better outcomes with continuous
Source: 2minutemedicine.com
